Cynthia Flanders

Director Cynthia Flanders sold 2,596 shares of AGX at $666.31 for $1,729,740.76 on 2026-06-15.

Cynthia Flanders, a director at Argan Inc, sold 2,596 shares at $666.31, reducing her holdings from 25,740 to 23,144 shares. The sale occurred when AGX is trading at $690.39, some 11.4% below its 52-week high of $779.00 and down 4.4% over the past 30 days despite a strong 47.0% gain over 90 days. Reviewing her prior trades specifically at AGX, of 5 previous transactions across 2023–2026, only 1 proved well-timed at the 90-day mark, suggesting inconsistent execution in timing sales at this ticker. Her cross-ticker track record shows a 0.00% well-timed rate on 4 prior sells, indicating that past sales have tended to be followed by price appreciation rather than declines. This latest transaction does not offer a clear directional signal about her conviction given the mixed historical outcomes at this specific ticker.

Director Cynthia Flanders sold 19,000 AGX shares at $386.70 (Jan 21, 2026) for $7.3M, reducing stake 42%

Director Cynthia Flanders executed a substantial open-market sale of 19,000 shares at $386.70 on 2026-01-21, totaling $7.3M and reducing her stake from 45,207 to 26,207 shares (42% reduction). The sale occurred near the 52-week high of $397.42, within -8.4% of the peak. Her prior sales at AGX show mixed timing outcomes: the October 2025 sale generated +14.6% and +21.5% returns post-transaction, while the June 2025 sale saw -3.7% at 30 days; of her five prior AGX trades, only one achieved favorable 90-day timing (sell before decline or buy before rise), indicating low predictive consistency at this ticker. The company's fundamentals remain robust with $251.2M quarterly revenue, +52.5% annual growth, and $30.7M net income, though at a P/E of 42.12, valuation pressure may be a consideration. The transaction alone does not signal immediate corporate distress but the significant position reduction warrants monitoring of any related filing motives or upcoming earnings revisions.

Director Cynthia Flanders sold 15,000 shares of AGX at $271.96 for $4.1M, reducing holdings by -47.7%

Flanders sold 15,000 shares (15.0K shares) at $271.96, cutting her position from 31,428 shares (31.4K shares) to 16,428 shares (16.4K shares)—a substantial -47.7% reduction in holdings. The stock has since rallied to $281.67 (current price), sitting at the 52-week high, and has posted strong momentum with 30-day +38.2% and 90-day +35.1% gains. Across her prior AGX trades, Flanders' timing has been inconsistent: her last AGX sale on 2023-10-05 was followed by +1.8% 90-day return (poorly timed), while her prior sales in the cross-ticker track record averaged +2.1% 90-day return (also poorly timed, with 0.00% well-timed rate). The company itself shows robust fundamentals with revenue of $237,743,000.00, net income of $35,275,000.00, and annual revenue growth of +52.5%, though the P/E of 33.18 reflects significant market expectations. Given the stock's recent strength and the director's substantial reduction in exposure at a valuation near 52-week highs, this transaction merits observation for whether it signals any shift in board-level confidence, though the data does not reveal clear timing acumen in Flanders' selling pattern.

Director Flanders sells 15,000 shares of AGX for $3.3M at $220.47; holds 33,428 shares post-sale (-31.0%)

Cynthia Flanders, a Director, sold 15,000 shares of Argan for $3.3M on 2025-06-12 at $220.47 per share, reducing her stake by 31.0% to 33,428 shares. At the current price of $212.82 (down 12.5% from the 52-week high of $243.11), the sale occurred near the upper end of recent trading ranges. Her prior transaction history at AGX shows mixed results: a 2023 sale achieved a -1.9% 30-day return and +1.8% 90-day return (well-timed by the metric), while simultaneous and prior buys achieved +67.9% and +74.1% 90-day gains and -4.5% and -2.0% respectively, suggesting inconsistent timing discipline. The company shows strong fundamentals with +52.5% annual revenue growth and a $2.9B market cap, which provides context for evaluating whether this divestiture reflects any operational concern or simply a routine liquidity event.